The market has climbed 2.0% in the last 7 days and has seen a remarkable 23% increase over the past year, with earnings expected to grow by 19% annually. While penny stocks may seem like a term from another era, they still offer intriguing opportunities for investors seeking growth at accessible price points. By focusing on companies with strong financials and solid fundamentals, these stocks can present hidden value without many of the typical risks associated with this segment of the market.

Let's uncover some gems from our specialized screener.

Anixa Biosciences (ANIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anixa Biosciences, Inc. is a biotechnology company that develops therapies and vaccines targeting critical unmet needs in oncology, with a market cap of $88.80 million.

Operations: Anixa Biosciences, Inc. currently does not report any revenue segments.

Market Cap: $88.8M

Anixa Biosciences, Inc., with a market cap of US$88.80 million, remains pre-revenue and unprofitable but has shown progress in reducing losses by 3.2% annually over the past five years. The company has a seasoned management team and board of directors, with average tenures of 8.9 and 7.7 years respectively, which supports strategic continuity in its innovative immunotherapy pipeline. Recent updates from ongoing clinical trials indicate promising safety and efficacy signals for its CAR-T therapy targeting ovarian cancer and a breast cancer vaccine advancing to Phase 2 trials following positive Phase 1 results, highlighting potential future revenue streams if successful.

Pyxis Oncology (PYXS)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics for the treatment of solid tumors, with a market cap of $110.87 million.

Operations: Currently, there are no revenue segments reported for this clinical-stage company focused on developing therapeutics for solid tumors.

Market Cap: $110.87M

Pyxis Oncology, Inc., with a market cap of US$110.87 million, is pre-revenue and currently unprofitable, reporting a net loss of US$23.27 million for Q1 2026. Despite no revenue streams yet, the company remains debt-free and its short-term assets exceed liabilities by US$29.1 million. The recent appointment of Nelson Azoulay as Chief Business Officer aims to enhance strategic development for MICVO, their lead clinical asset in solid tumor treatment trials. However, concerns about financial sustainability persist due to doubts over its ability to continue as a going concern raised by auditors in March 2026.

Xtra-Gold Resources (XTGR.F)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Xtra-Gold Resources Corp. is a gold exploration company operating in Ghana with a market cap of $89.29 million.

Operations: Xtra-Gold Resources Corp. does not report any specific revenue segments.

Market Cap: $89.29M

Xtra-Gold Resources Corp., with a market cap of US$89.29 million, is pre-revenue, generating less than US$1 million in revenue. Despite this, the company reported net income of US$1.21 million for Q1 2026 and has demonstrated significant earnings growth over the past five years at an annual rate of 23.1%. The company remains debt-free and its short-term assets of US$18.2 million comfortably cover liabilities of US$1.7 million, indicating strong financial stability. Xtra-Gold's management and board are experienced, with average tenures exceeding industry norms, supporting strategic execution in gold exploration activities in Ghana.

Next Steps

• Navigate through the entire inventory of 336 US Penny Stocks here.
• Ready To Venture Into Other Investment Styles? Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.